Metraipolis › archive › dc_de130dbdbb30

Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir… — Europe PMC PMID:41321121

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41321121
DOI
10.1093/cid/ciaf632
License (as archived)
solo-consultazione
Archived
2026-11-06T08:38:04.465Z
SHA-256 of the archived text
c56f7e6c4297ae35e7a058891ea528f575dece1aa51a1d945483b964963d0ff7
Stable URL of this page
https://metraipolis.com/documento/dc_de130dbdbb30

How to cite

Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir… — Europe PMC PMID:41321121 — Europe PMC (en), https://europepmc.org/article/MED/41321121 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_de130dbdbb30 (Metraipolis archive dc_de130dbdbb30, sha256 c56f7e6c4297ae35e7a058891ea528f575dece1aa51a1d945483b964963d0ff7)
BibTeX
@misc{dcde130dbdbb30,
  title = {Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir… — Europe PMC PMID:41321121},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41321121},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_de130dbdbb30; sha256 c56f7e6c4297ae35e7a058891ea528f575dece1aa51a1d945483b964963d0ff7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41321121. Agents can read the archived copy with the MCP tool read_document.